Dermata Therapeutics, Inc. (NASDAQ:DRMA) Short Interest Update

Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 319,014 shares, a drop of 57.6% from the December 31st total of 752,424 shares. Based on an average trading volume of 206,384 shares, the days-to-cover ratio is currently 1.5 days. Approximately 38.2% of the shares of the stock are short sold. Approximately 38.2% of the shares of the stock are short sold. Based on an average trading volume of 206,384 shares, the days-to-cover ratio is currently 1.5 days.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Dermata Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $10.00.

Dermata Therapeutics Price Performance

Dermata Therapeutics stock traded down $0.56 during trading hours on Friday, hitting $2.25. The company had a trading volume of 958,046 shares, compared to its average volume of 1,852,935. Dermata Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $23.70. The firm’s fifty day moving average is $2.46 and its 200-day moving average is $4.19. The firm has a market capitalization of $2.32 million, a P/E ratio of -0.29 and a beta of 0.54.

Dermata Therapeutics (NASDAQ:DRMA) last issued its earnings results on Friday, November 14th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.59) by ($0.06).

Dermata Therapeutics Company Profile

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.